Table 1 Baseline and treatment characteristics
Variable | No ACEi/ARB | ACEi | ARB | Total |
|---|---|---|---|---|
N | 270 | 29 | 22 | 321 |
Demographics and clinical factors | ||||
Age (years) | 62.0 (15.40) | 61.6 (15.69) | 67.8 (13.98) | 62.3 (15.36) |
Female—n (%) | 103 (38.1%) | 11 (36.7%) | 13 (59.1%) | 126 (39.3%) |
Body mass index (kg/m2) | 29.8 (8.47) | 32.5 (10.92) | 33.6 (8.95) | 30.3 (8.80) |
Ideal body weight (kg) | 64.2 (11.69) | 66.3 (11.24) | 61.6 (9.24) | 64.3 (11.51) |
Cause of vasodilatory shock—n (%) | ||||
Sepsis | 218 (80.7%) | 24 (80.0%) | 18 (81.8%) | 259 (80.7%) |
Other—potentially sepsis | 28 (10.4%) | 1 (3.3%) | 2 (9.1%) | 31 (9.7%) |
Other—not sepsis | 24 (8.9%) | 5 (16.7%) | 2 (9.1%) | 31 (9.7%) |
Baseline APACHE II Score | 28.2 (8.59) | 27.1 (7.55) | 26.7 (6.83) | 28.0 (8.37) |
Baseline albumin (g/dl) | 2.3 (0.63) | 2.5 (0.51) | 2.2 (0.45) | 2.3 (0.61) |
ARDS at baseline—n (%) | 70 (25.9%) | 2 (6.7%) | 9 (40.9%) | 81 (25.2%) |
Intubated at baseline—n (%) | 249 (92.2%) | 28 (93.3%) | 19 (86.4%) | 295 (91.9%) |
RRT at screening—n (%) | 79 (29.3%) | 11 (36.7%) | 8 (36.4%) | 98 (30.5%) |
Baseline cardiovascular status | ||||
Mean arterial pressure (mmHg) | 65.7 (5.46) | 67.7 (6.23) | 65.7 (2.95) | 65.9 (5.42) |
Baseline NED (µg/kg/min) | 0.47 (0.412) | 0.44 (0.304) | 0.43 (0.378) | 0.46 (0.400) |
Average NED in past 6 h (µg/kg/min) | 0.51 (0.399) | 0.53 (0.286) | 0.49 (0.301) | 0.51 (0.383) |
Vasopressin use in past 6 h—n (%) | 188 (69.6%) | 20 (66.7%) | 17 (77.3%) | 224 (69.8%) |
Central venous pressure (mmHg) | 13.5 (5.01) | 12.1 (2.72) | 11.9 (5.31) | 13.3 (4.88) |
Cardiac index (L/min/m2) ScvO2 (%) | 3.3 (0.93) | 3.6 (1.35) | 3.6 (1.12) | 3.4 (0.97) |
Medical history | ||||
Hypertension—n (%) | 139 (51.5%) | 23 (76.7%) | 22 (100.0%) | 183 (57.0%) |
Chronic kidney Disease—n (%) | 66 (24.4%) | 11 (36.7%) | 7 (31.8%) | 84 (26.2%) |
Diabetes—n (%) | 90 (33.3%) | 14 (46.7%) | 9 (40.9%) | 112 (34.9%) |
Coronary artery disease—n (%) | 70 (25.9%) | 10 (33.3%) | 3 (13.6%) | 83 (25.9%) |
Chronic Heart Failure—n (%) | 49 (18.1%) | 8 (26.7%) | 2 (9.1%) | 59 (18.4%) |
Baseline lab values | ||||
WBC (109/L)—Med [IQR] | 16.7 [10.0, 25.3] | 19.2 [13.8, 27.4] | 17.0 [12.4, 22.5] | 17.2 [10.6, 25.6] |
Hemoglobin (g/dL)— Med [IQR] | 9.8 [8.5, 11.2] | 9.3 [7.9, 11.7] | 10.2 [9.1, 11.0] | 9.8 [8.5, 11.2] |
Potassium (mEq/L)—Med [IQR] | 4.2 [3.8, 4.8] | 4.4 [3.9, 4.7] | 4.5 [3.9, 4.9] | 4.2 [3.8, 4.8] |
Creatinine (mg/dL)— Med [IQR] | 1.9 [1.2, 2.8] | 2.4 [1.4, 3.4] | 3.0 [1.8, 4.0] | 2.1 [1.2, 2.9] |
BUN (mg/dL)—Med [IQR] | 25 [15, 43] | 33 [13, 44] | 22 [17, 30] | 25 [15, 43] |
Bicarbonate (mEq/L)—Med [IQR] | 20 [15, 23] | 19.0 [15, 21] | 18 [16, 20] | 19 [15, 22] |
P/F Ratio (mmHg)—Med [IQR] | 210 [138, 288] | 261 [186, 318] | 212 [114, 280] | 211 [140, 296] |
Treatment characteristics | ||||
Duration of study drug exposure (hr)—Med [IQR] | 48.1 [35.5, 49.3] | 48.0 [28.5, 48.4] | 42.7 [29.1, 48.0] | 48.0 [35.0, 49.2] |
Fluid administration (mL)—Med [IQR] | 521 [319, 789] | 497 [257, 913] | 537 [433, 664] | 525 [319, 784] |